Corcept Therapeutics Incorporated (CORT): Price and Financial Metrics

Corcept Therapeutics Incorporated (CORT): $23.08

0.11 (+0.48%)

POWR Rating

Component Grades








Add CORT to Watchlist
Sign Up

Industry: Biotech




#20 of 380

in industry

CORT Price/Volume Stats

Current price $23.08 52-week high $30.14
Prev. close $22.97 52-week low $17.86
Day low $22.81 Volume 194,458
Day high $23.21 Avg. volume 770,711
50-day MA $22.93 Dividend yield N/A
200-day MA $23.83 Market Cap 2.34B

CORT Stock Price Chart Interactive Chart >


  • Quality is the dimension where CORT ranks best; there it ranks ahead of 99.85% of US stocks.
  • The strongest trend for CORT is in Sentiment, which has been heading down over the past 179 days.
  • CORT ranks lowest in Growth; there it ranks in the 7th percentile.

CORT Stock Summary

  • For CORT, its debt to operating expenses ratio is greater than that reported by merely 3.86% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.15 for CORCEPT THERAPEUTICS INC; that's greater than it is for merely 11.16% of US stocks.
  • With a year-over-year growth in debt of -79.58%, CORCEPT THERAPEUTICS INC's debt growth rate surpasses just 2.36% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CORCEPT THERAPEUTICS INC are ALRM, HLIT, AGYS, FORM, and MNTS.
  • CORT's SEC filings can be seen here. And to visit CORCEPT THERAPEUTICS INC's official web site, go to

CORT Valuation Summary

  • CORT's price/sales ratio is 6.2; this is 21.57% higher than that of the median Healthcare stock.
  • CORT's EV/EBIT ratio has moved up 50.3 over the prior 233 months.

Below are key valuation metrics over time for CORT.

Stock Date P/S P/B P/E EV/EBIT
CORT 2023-05-23 6.2 4.8 27.1 22.4
CORT 2023-05-22 6.0 4.7 26.5 21.9
CORT 2023-05-19 5.9 4.6 26.0 21.4
CORT 2023-05-18 5.9 4.6 25.9 21.3
CORT 2023-05-17 6.0 4.7 26.3 21.7
CORT 2023-05-16 6.0 4.7 26.2 21.6

CORT Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 122.45%.
  • Its year over year net cashflow from operations growth rate is now at 23.31%.
  • Its 4 year net cashflow from operations growth rate is now at 490.98%.
CORT's revenue has moved up $308,998,000 over the prior 70 months.

The table below shows CORT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 401.858 120.323 101.288
2022-09-30 397.624 136.362 116.798
2022-06-30 392.027 151.418 112.719
2022-03-31 380.229 177.717 111.844
2021-12-31 365.978 167.892 112.512
2021-09-30 352.891 153.536 106.453

CORT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CORT has a Quality Grade of A, ranking ahead of 98.86% of graded US stocks.
  • CORT's asset turnover comes in at 0.616 -- ranking 52nd of 681 Pharmaceutical Products stocks.
  • OTIC, ABT, and AVDL are the stocks whose asset turnover ratios are most correlated with CORT.

The table below shows CORT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.616 0.985 0.237
2021-03-31 0.631 0.985 0.248
2020-12-31 0.691 0.984 0.312
2020-09-30 0.754 0.984 0.345
2020-06-30 0.816 0.983 0.413
2020-03-31 0.862 0.982 0.432

CORT Price Target

For more insight on analysts targets of CORT, see our CORT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.25 Average Broker Recommendation 1.75 (Moderate Buy)

Corcept Therapeutics Incorporated (CORT) Company Bio

Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.

CORT Latest News Stream

Event/Time News Detail
Loading, please wait...

CORT Latest Social Stream

Loading social stream, please wait...

View Full CORT Social Stream

Latest CORT News From Around the Web

Below are the latest news stories about CORCEPT THERAPEUTICS INC that investors may wish to consider to help them evaluate CORT as an investment opportunity.

Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.

Yahoo | May 4, 2023

Q1 2023 Corcept Therapeutics Inc Earnings Call

Q1 2023 Corcept Therapeutics Inc Earnings Call

Yahoo | May 4, 2023

Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of -30% and 1.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 3, 2023

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2023. Financial Results Revenue of $105.7 million, compared to $93.7 million in first quarter 2022 Raised 2023 revenue guidance t

Yahoo | May 3, 2023

Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | April 27, 2023

Read More 'CORT' Stories Here

CORT Price Returns

1-mo -0.09%
3-mo 20.21%
6-mo -7.61%
1-year 9.90%
3-year 61.17%
5-year 24.76%
YTD 13.64%
2022 2.58%
2021 -24.31%
2020 116.20%
2019 -9.43%
2018 -26.02%

Continue Researching CORT

Here are a few links from around the web to help you further your research on Corcept Therapeutics Inc's stock as an investment opportunity:

Corcept Therapeutics Inc (CORT) Stock Price | Nasdaq
Corcept Therapeutics Inc (CORT) Stock Quote, History and News - Yahoo Finance
Corcept Therapeutics Inc (CORT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!